{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:49:46Z","timestamp":1792133386066,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Recommended pharmacotherapy for hypothyroidism in Hashimoto\u2019s thyroiditis (HT) is oral supplementation with levothyroxine (LT-4). However, serum thyrotropin (TSH) levels within normal range are not consistently achieved with LT-4 medication.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and methods<\/jats:title>\n                <jats:p>We report on 35 HT patients with LT-4 therapy in this retrospective evaluation. In general, we recommend that a maximum of two sips of water, which would then amount to &lt; 50\u2009mL, be ingested at the same time as LT-4. We report on follow up examinations measuring TSH and antibodies against thyroid peroxidase (TPOAb) after 6 months to five years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After median time of 643 days (range 98-1825) we found in 35 HT patients a statistical significant reduction of serum TSH (p\u2009&lt;\u20090.001) and TPOAb (p\u2009=\u20090.006). The patients median body weight was 71\u2009kg (range 48\u201398) and a daily LT-4 dosage was used with median 69.1\u2009\u00b5g (range 25\u2013150). This results in a daily LT-4 dose of median 1.01\u2009\u00b5g\/kg bodyweight (range 0.3\u20132.3).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The reduction of water ingestion to a maximum of two sips, which is &lt;50\u2009mL, combined with LT-4 supplementation helps to achieve euthyroidism in HT. In addition, it reduces the L-T4 medication dosage needed to lower TSH serum levels and decreases TPO antibodies in HT.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12020-024-03829-w","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T12:01:55Z","timestamp":1713441715000},"page":"233-238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["One sip of water with LT-4 supplementation\u2014a key to euthyroidism in Hashimoto\u2019s thyroiditis"],"prefix":"10.1007","volume":"86","author":[{"given":"Wolfgang J.","family":"Schnedl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Michaelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Mangge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Enko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"issue":"6","key":"3829_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2019.101367","volume":"33","author":"F Ragusa","year":"2019","unstructured":"F. Ragusa, P. Fallahi, G. Elia, D. Gonnella, S.R. Paparo, C. Giusti, L.P. Churilov, S.M. Ferrari, A. Antonelli, Hashimoto\u2019s thyroiditis: Epidemiology, pathogenesis, clinic and therapy. Best Pract. Res. Clin. Endocrinol. Metab. 33(6), 101367 (2019). https:\/\/doi.org\/10.1016\/j.beem.2019.101367","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"12","key":"3829_CR2","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1089\/thy.2014.0028","volume":"24","author":"J Jonklaas","year":"2014","unstructured":"J. Jonklaas, A.C. Bianco, A.J. Bauer, K.D. Burman, A.R. Cappola, F.S. Celi, D.S. Cooper, B.W. Kim, R.P. Peeters, M.S. Rosenthal, A.M. Sawka, Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid 24(12), 1670\u20131751 (2014). https:\/\/doi.org\/10.1089\/thy.2014.0028","journal-title":"Thyroid"},{"issue":"4","key":"3829_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000356507","volume":"2","author":"SH Pearce","year":"2013","unstructured":"S.H. Pearce, G. Brabant, L.H. Duntas, F. Monzani, R.P. Peeters, S. Razvi, J.L. Wemeau, ETA Guideline: management of subclinical hypothyroidism. Eur. Thyroid J. 2(4), 215\u2013228 (2013). https:\/\/doi.org\/10.1159\/000356507","journal-title":"Eur. Thyroid J."},{"issue":"2","key":"3829_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s12020-021-02851-6","volume":"74","author":"SP Fitzgerald","year":"2021","unstructured":"S.P. Fitzgerald, N.G. Bean, J.V. Hennessey, H. Falhammar, Thyroid testing paradigm switch from thyrotropin to thyroid hormones - Future directions and opportunities in clinical medicine and research. Endocrine 74(2), 285\u20139 (2021). https:\/\/doi.org\/10.1007\/s12020-021-02851-6","journal-title":"Endocrine"},{"issue":"2","key":"3829_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3121\/cmr.2016.1309","volume":"14","author":"MT Sheehan","year":"2016","unstructured":"M.T. Sheehan, Biochemical Testing of the Thyroid: TSH is the best and, oftentimes, only test needed - A review for primary care. Clin. Med. Res. 14(2), 83\u201392 (2016). https:\/\/doi.org\/10.3121\/cmr.2016.1309","journal-title":"Clin. Med. Res."},{"key":"3829_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s12325-019-01078-2","volume":"36","author":"LH Duntas","year":"2019","unstructured":"L.H. Duntas, J. Jonklaas, Levothyroxine dose adjustment to optimise therapy throughout a patient\u2019s lifetime. Adv. Ther. 36, 30\u201346 (2019). https:\/\/doi.org\/10.1007\/s12325-019-01078-2","journal-title":"Adv. Ther."},{"issue":"1","key":"3829_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12020-022-03056-1","volume":"77","author":"C Virili","year":"2022","unstructured":"C. Virili, G. Bruno, M.G. Santaguida, L. Gargano, I. Stramazzo, C. De Vito, A. Cicenia, G. Scalese, B. Porowska, C. Severi, M. Centanni, Levothyroxine treatment and gastric juice pH in humans: the proof of concept. Endocrine 77(1), 102\u2013111 (2022). https:\/\/doi.org\/10.1007\/s12020-022-03056-1","journal-title":"Endocrine"},{"issue":"7","key":"3829_CR8","doi-asserted-by":"publisher","first-page":"453","DOI":"10.7326\/M18-0284","volume":"170","author":"I Guldvog","year":"2019","unstructured":"I. Guldvog, L.C. Reitsma, L. Johnsen, A. Lauzike, C. Gibbs, E. Carlsen, T.H. Lende, J.K. Narvestad, R. Omdal, J.T. Kval\u00f8y, G. Hoff, T. Bernklev, H. S\u00f8iland, Thyroidectomy versus medical management for euthyroid patients with Hashimoto disease and persisting symptoms: A randomized trial. Ann. Intern. Med. 170(7), 453\u2013464 (2019). https:\/\/doi.org\/10.7326\/M18-0284","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"3829_CR9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S2213-8587(18)30371-1","volume":"7","author":"J Jonklaas","year":"2019","unstructured":"J. Jonklaas, S. Razvi, Reference intervals in the diagnosis of thyroid dysfunction: treating patients not numbers. Lancet Diabetes Endocrinol 7(6), 473\u201383 (2019). https:\/\/doi.org\/10.1016\/S2213-8587(18)30371-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"3829_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2478\/enr-2022-0009","volume":"56","author":"RM Garcia-Moreno","year":"2022","unstructured":"R.M. Garcia-Moreno, A.I. Cos-Blanco, I. Calvo-Vinuela, M. Zapatero-Larrauri, L. Herranz, Change in levothyroxine requirements after bariatric surgery in patients with hypothyroidism. Endocr. Regul. 56(2), 81\u20136 (2022). https:\/\/doi.org\/10.2478\/enr-2022-0009","journal-title":"Endocr. Regul."},{"issue":"1","key":"3829_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s13679-023-00548-7","volume":"13","author":"E Dvo\u0159\u00e1\u010dkov\u00e1","year":"2024","unstructured":"E. Dvo\u0159\u00e1\u010dkov\u00e1, A. Pilkov\u00e1, M. Matoulek, O. Slana\u0159, J.M. Hartinger, Bioavailability of orally administered drugs after bariatric surgery. Curr. Obes. Rep. 13(1), 141\u2013153 (2024). https:\/\/doi.org\/10.1007\/s13679-023-00548-7","journal-title":"Curr. Obes. Rep."},{"issue":"1","key":"3829_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s11695-023-06970-z","volume":"34","author":"M Almukainzi","year":"2024","unstructured":"M. Almukainzi, R. AlQahtani, R. Alanazi, R. Alamri, H. Alayed, Insight of the biopharmaceutical implication of sleeve gastrectomy on levothyroxine absorption in hypothyroidism patients. Obes. Surg. 34(1), 192\u2013197 (2024). https:\/\/doi.org\/10.1007\/s11695-023-06970-z","journal-title":"Obes. Surg."},{"issue":"12","key":"3829_CR13","doi-asserted-by":"publisher","first-page":"e220355","DOI":"10.1530\/EC-22-0355","volume":"11","author":"S Santos Monteiro","year":"2022","unstructured":"S. Santos Monteiro, T.S. Santos, A.M. Lopes, J.C. Oliveira, C. Freitas, A. Couto Carvalho, Levothyroxine malabsorption or pseudomalabsorption? A question in the management of refractory hypothyroidism. Endocr. Connect. 11(12), e220355 (2022). https:\/\/doi.org\/10.1530\/EC-22-0355","journal-title":"Endocr. Connect."},{"issue":"1","key":"3829_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.15403\/jgld.2014.1121.fio","volume":"24","author":"G Fiorini","year":"2015","unstructured":"G. Fiorini, J.M. Bland, E. Hughes, V. Castelli, D. Vaira, A systematic review on drugs absorption modifications after eradication in Helicobacter pylori positive patients undergoing replacement therapy. J Gastrointestin. Liver Dis 24(1), 95\u2013100 (2015). https:\/\/doi.org\/10.15403\/jgld.2014.1121.fio","journal-title":"J Gastrointestin. Liver Dis"},{"issue":"5","key":"3829_CR15","doi-asserted-by":"publisher","first-page":"844","DOI":"10.18433\/j36p5m","volume":"18","author":"C Seng Yue","year":"2015","unstructured":"C. Seng Yue, S. Benvenga, C. Scarsi, L. Loprete, M.P. Ducharme, When bioequivalence in healthy volunteers may not translate to bioequivalence in patients: Differential effects of increased gastric pH on the pharmacokinetics of levothyroxine capsules and tablets. J. Pharm. Pharm. Sci. 18(5), 844\u201355 (2015). https:\/\/doi.org\/10.18433\/j36p5m","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"5","key":"3829_CR16","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/MED.0000000000000558","volume":"27","author":"MJ Ritter","year":"2020","unstructured":"M.J. Ritter, S. Gupta, J.V. Hennessey, Alternative routes of levothyroxine administration for hypothyroidism. Curr. Opin. Endocrinol. Diabetes Obes. 27(5), 318\u2013322 (2020). https:\/\/doi.org\/10.1097\/MED.0000000000000558","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"3","key":"3829_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1210\/endrev\/bnac030","volume":"44","author":"H Liu","year":"2023","unstructured":"H. Liu, W. Li, W. Zhang, S. Sun, C. Chen, Levothyroxine: Conventional and novel drug delivery formulations. Endocr. Rev. 44(3), 393\u2013416 (2023). https:\/\/doi.org\/10.1210\/endrev\/bnac030","journal-title":"Endocr. Rev."},{"issue":"12","key":"3829_CR18","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.3390\/jcm11123479","volume":"11","author":"P Trimboli","year":"2022","unstructured":"P. Trimboli, S. Mouly, Pharmacokinetics and clinical implications of two non-tablet oral formulations of L-thyroxine in patients with hypothyroidism. J. Clin. Med. 11(12), 3479 (2022). https:\/\/doi.org\/10.3390\/jcm11123479","journal-title":"J. Clin. Med."},{"issue":"3","key":"3829_CR19","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11154-021-09691-9","volume":"23","author":"P Caron","year":"2022","unstructured":"P. Caron, S. Grunenwald, L. Persani, F. Borson-Chazot, R. Leroy, L. Duntas, Factors influencing the levothyroxine dose in the hormone replacement therapy of primary hypothyroidism in adults. Rev. Endocr. Metab. Disord. 23(3), 463\u2013483 (2022). https:\/\/doi.org\/10.1007\/s11154-021-09691-9","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"3829_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1054983","volume":"13","author":"GJ Kahaly","year":"2022","unstructured":"G.J. Kahaly, U. Gottwald-Hostalek, Use of levothyroxine in the management of hypothyroidism: A historical perspective. Front. Endocrinol. (Lausanne). 13, 1054983 (2022). https:\/\/doi.org\/10.3389\/fendo.2022.1054983","journal-title":"Front. Endocrinol. (Lausanne)."},{"key":"3829_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.626371","volume":"12","author":"P Fallahi","year":"2021","unstructured":"P. Fallahi, S.M. Ferrari, G. Elia, F. Ragusa, S.R. Paparo, A. Antonelli, L-T4 therapy in enteric malabsorptive disorders. Front. Endocrinol. 12, 626371 (2021). https:\/\/doi.org\/10.3389\/fendo.2021.626371","journal-title":"Front. Endocrinol."},{"issue":"7","key":"3829_CR22","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1089\/thy.2012.0435","volume":"23","author":"CL Perez","year":"2013","unstructured":"C.L. Perez, F.S. Araki, H. Graf, G.A. de Carvalho, Serum thyrotropin levels following levothyroxine administration at breakfast. Thyroid 23(7), 779\u201384 (2013). https:\/\/doi.org\/10.1089\/thy.2012.0435","journal-title":"Thyroid"},{"issue":"10","key":"3829_CR23","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1210\/jc.2009-0860","volume":"94","author":"TG Bach-Huynh","year":"2009","unstructured":"T.G. Bach-Huynh, B. Nayak, J. Loh, S. Soldin, J. Jonklaas, Timing of levothyroxine administration affects serum thyrotropin concentration. J. Clin. Endocrinol. Metab. 94(10), 3905\u201312 (2009). https:\/\/doi.org\/10.1210\/jc.2009-0860","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"3829_CR24","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/psp4.12959","volume":"12","author":"E Yang","year":"2023","unstructured":"E. Yang, K.S. Yu, S. Lee, Prediction of gastric pH-mediated drug exposure using physiologically-based pharmacokinetic modeling: A case study of itraconazole. CPT Pharmacometrics Syst. Pharmacol. 12(6), 865\u2013877 (2023). https:\/\/doi.org\/10.1002\/psp4.12959","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"3829_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.621616","volume":"11","author":"C Virili","year":"2021","unstructured":"C. Virili, N. Brusca, S. Capriello, M. Centanni, Levothyroxine therapy in gastric malabsorptive disorders. Front. Endocrinol. (Lausanne). 11, 621616 (2021). https:\/\/doi.org\/10.3389\/fendo.2020.621616","journal-title":"Front. Endocrinol. (Lausanne)."},{"issue":"10","key":"3829_CR26","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1021\/acs.molpharmaceut.7b00593","volume":"14","author":"D Kou","year":"2017","unstructured":"D. Kou, S. Dwaraknath, Y. Fischer, D. Nguyen, M. Kim, H. Yiu, P. Patel, T. Ng, C. Mao, M. Durk, L. Chinn, H. Winter, L. Wigman, P. Yehl, Biorelevant dissolution models for a weak base to facilitate formulation development and overcome reduced bioavailability caused by hypochlordyria or achlorhydria. Mol. Pharm. 14(10), 3577\u20133587 (2017). https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00593","journal-title":"Mol. Pharm."},{"issue":"6","key":"3829_CR27","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s11095-016-1882-8","volume":"33","author":"C Litou","year":"2016","unstructured":"C. Litou, M. Vertzoni, C. Goumas, V. Vasdekis, W. Xu, F. Kesisoglou, C. Reppas, Characteristics of the human upper gastrointestinal contents in the fasted state under hypo- and achlorhydric gastric conditions under conditions of typical drug - drug interaction studies. Pharm. Res. 33(6), 1399\u2013412 (2016). https:\/\/doi.org\/10.1007\/s11095-016-1882-8","journal-title":"Pharm. Res."},{"key":"3829_CR28","unstructured":"Levothyroxine - Thyrex\u00ae; German, accessed January 25, 2024."},{"key":"3829_CR29","unstructured":"Euthyrox\u00ae (Levothyroxin Natrium) | Merck (merckgroup.com); German, accessed January 25, 2024."},{"issue":"3","key":"3829_CR30","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00455-002-0105-0","volume":"18","author":"HT Lawless","year":"2003","unstructured":"H.T. Lawless, S. Bender, C. Oman, C. Pelletier, Gender, age, vessel size, cup vs. straw sipping, and sequence effects on sip volume. Dysphagia 18(3), 196\u2013202 (2003). https:\/\/doi.org\/10.1007\/s00455-002-0105-0","journal-title":"Dysphagia"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03829-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-03829-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03829-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T05:37:07Z","timestamp":1727761027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-03829-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["3829"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-03829-w","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"assertion":[{"value":"27 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable as this is a purely observational, retrospective study based on existing data. The study follows the ethical guidelines of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}